How to Cite
Abstract
INTRODUCTION: The goal of the study was to assess the feasibility of combined treatment in patients with a complicated course of locally advanced and recurrent colorectal cancer.
METHODS: A case-control study was conducted. The study group included patients with locally advanced or recurrent rectal cancer complicated by external, rectovesical, rectovaginal fistulas and/or peritumoral abscesses received neoadjuvant chemoradiation (CRT). Patients without complications comparable to the study group by sex, age, ECOG status, cT value, and the nature of the tumor (primary/recurrent) treated with neoadjuvant CRT were selected in the control group. The primary end points of the study were CRT toxicity (NCI-CTC v.4.0) and postoperative complications (Clavien-Dindo). The secondary endpoints of the study were the pathologic complete response rate 2-year progression-free survival.
RESULTS: 21 patients were included in both groups. In the study group the following complications were noted: external fistula (n = 7), rectovaginal fistula (n = 6), rectovesical fistula (n = 4), paraproctitis (n = 4), peritumoral abscess (n = 13), 16 patients (76%) required additional treatment prior the CRT: preventive colostomy (n = 14), antibacterial therapy (n = 5). Grade 3 toxicity was observed in 2 (9,52%) patients and in the study group (p = 1). Postoperative mortality was not registered in both groups. Postoperative grade III and higher complications in the study group were observed in 1 (5,2%) patient and in 3 patients (15,7) in the comtrol group (p = 0.129). 19 patients underwent surgery in each group, R0-resection was achieved in 17 patients in the study group and 19 in the control group. Pathological complete response was registered in 1 (5,2%) patient in the study group and in 4 patients in the control group (21,5%) (p = 0,14). Median progression-free survival was not achieved in both groups.
CONCLUSION: the combined treatment of complicated locally advanced and recurrent rectal cancer after appropriate planning and concomitant symptomatic therapy does not increase the toxicity profile and postoperative complications rate.
References
Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ. - Москва: издательская группа РОНЦ, 2014. - 226 с.
Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в россии в 2015 году (заболеваемость и смертность). - Москва: Мниои им. П.А. Герцена филиал ФГБУ «НМИРЦ» Минздрава россии, 2017.
Benjelloun E.B., Aitalalim S., Chbani L. et al. Rectosigmoid adenocarcinoma revealed by metastatic anal fistula. The visible part of the iceberg: a report of two cases with literature review // World Journal of surgical oncology. - 2012. - Vol. 10. - P. 209-209.
Kennecke H., Berry S., Wong R. et al. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial // Eur. J. Cancer. - 2012. - Vol. 48. - № 1. - P. 37-45.
Kitahara I., Uemura M., Haraguchi N. et al. successful treatment of rectal cancer with perineal invasion: Three case reports // Molecular and clinical oncology. - 2014. - Vol. 2. - № 4. - P. 497-500.
Miyakawa T., Lida S., Igaki T. et al. Neoadjuvant Chemoradiotherapy for Locally Advanced Carcinoma Associated with Anal Fistula // Gan To Kagaku Ryoho. - 2017. - Vol. 44. - № 12. - P. 1437-1439.
Murata A., Takatsuka S., Shinkawa H. et al. A case report of metastatic anal fistula cancer treated with neoadjuvant chemotherapy // Gan To Kagaku Ryoho. - 2014. - Vol. 41. - № 12. - P. 1869-1871.
Nushijima Y., Nakano K., Sugimoto K. et al. A case of primary carcinoma associated with anal fistula // Gan To Kagaku Ryoho. - 2014. - Vol. 41. - № 12. - P. 1872-1874.
Pfeiffer P. High-dose radiotherapy and concurrent UFT plus l-leucovorin in locally advanced rectal cancer: A phase I trial // Acta Oncologica. - 2005. - Vool. 44. - № 3. - P. 224-229.
Rodel C., Graeven U., Fietkau R. et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAo/ARo/AIo-04 study): final results of the multicentre, open-label, randomised, phase 3 trial // Lancet Oncol. - 2015. - Vol. 16. - № 8. - P. 979-989.
Vestermark L. W., Jensen H. A., Pfeiffer P. High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with nonresectable locally advanced rectal cancer (LARC): a phase I trial // Acta Oncol. - 2012. - Vol. 51. - № 3. - P. 311-317.
Yaegashi M., Otsuka K., Kimura T. et al. A Case of More Than Five-Year survival of Carcinoma Associated with Anal Fistula Effectively Treated by Combined Modality Therapy // Gan To Kagaku Ryoho. - 2017. - Vol. 44. - № 12. - P. 1754-1756.
Zhan T., Wang L., Li M. et al. A multidisciplinary clinical treatment of locally advanced rectal cancer complicated with rectovesical fistula: a case report // J. Med. Case Rep. - 2012. - Vol. 6. - P. 369.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2019